Direct modulation of epidermal growth factor binding by cholecystokinin

Murray Korc, Lynn M. Matrisian, Bruce E. Magun

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effects of cholecystokinin-octapeptide (CCK8), the biologically active C-terminal moiety of cholecystokinin (CCK), on the binding of epidermal growth factor (EGF) were studied in isolated rat pancreatic acini. CCK8 inhibited 125I-EGF binding in a dose-dependent manner. One-half maximal inhibition occurred at 5 × 10-10M, and maximal inhibition at 10-8M CCK8. This inhibitory effect was detectable within 5 minutes of addition of CCK8, and was not associated with enhanced degradation of 125I-EGF in incubation media. Unlabeled EGF exerted only a slightly greater inhibitory effect than CCK8 on 125I-EGF binding at equivalent molar concentrations. In contrast to CCK8, the gastrointestinal hormone vasoactive intestinal polypeptide (VIP) did not significantly alter EGF binding. CCK8 also inhibited EGF binding in mouse pancreatic acini, but did not alter binding in A-431 human carcinoma cells. These findings suggest that physiological levels of CCK may regulate EGF binding in the pancreas and other tissues with receptors for both hormones. They thus point to a previously unrecognized mechanism for hormonal interaction.

Original languageEnglish (US)
Pages (from-to)561-568
Number of pages8
JournalLife Sciences
Volume33
Issue number6
DOIs
StatePublished - Aug 8 1983
Externally publishedYes

Fingerprint

Cholecystokinin
Epidermal Growth Factor
Modulation
Gastrointestinal Hormones
Sincalide
Vasoactive Intestinal Peptide
Rats
Pancreas
Cells
Hormones
Tissue
Carcinoma
Degradation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Direct modulation of epidermal growth factor binding by cholecystokinin. / Korc, Murray; Matrisian, Lynn M.; Magun, Bruce E.

In: Life Sciences, Vol. 33, No. 6, 08.08.1983, p. 561-568.

Research output: Contribution to journalArticle

Korc, Murray ; Matrisian, Lynn M. ; Magun, Bruce E. / Direct modulation of epidermal growth factor binding by cholecystokinin. In: Life Sciences. 1983 ; Vol. 33, No. 6. pp. 561-568.
@article{62cd44116c7e48ecab88d47e49e20e5e,
title = "Direct modulation of epidermal growth factor binding by cholecystokinin",
abstract = "The effects of cholecystokinin-octapeptide (CCK8), the biologically active C-terminal moiety of cholecystokinin (CCK), on the binding of epidermal growth factor (EGF) were studied in isolated rat pancreatic acini. CCK8 inhibited 125I-EGF binding in a dose-dependent manner. One-half maximal inhibition occurred at 5 × 10-10M, and maximal inhibition at 10-8M CCK8. This inhibitory effect was detectable within 5 minutes of addition of CCK8, and was not associated with enhanced degradation of 125I-EGF in incubation media. Unlabeled EGF exerted only a slightly greater inhibitory effect than CCK8 on 125I-EGF binding at equivalent molar concentrations. In contrast to CCK8, the gastrointestinal hormone vasoactive intestinal polypeptide (VIP) did not significantly alter EGF binding. CCK8 also inhibited EGF binding in mouse pancreatic acini, but did not alter binding in A-431 human carcinoma cells. These findings suggest that physiological levels of CCK may regulate EGF binding in the pancreas and other tissues with receptors for both hormones. They thus point to a previously unrecognized mechanism for hormonal interaction.",
author = "Murray Korc and Matrisian, {Lynn M.} and Magun, {Bruce E.}",
year = "1983",
month = "8",
day = "8",
doi = "10.1016/0024-3205(83)90131-5",
language = "English (US)",
volume = "33",
pages = "561--568",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Direct modulation of epidermal growth factor binding by cholecystokinin

AU - Korc, Murray

AU - Matrisian, Lynn M.

AU - Magun, Bruce E.

PY - 1983/8/8

Y1 - 1983/8/8

N2 - The effects of cholecystokinin-octapeptide (CCK8), the biologically active C-terminal moiety of cholecystokinin (CCK), on the binding of epidermal growth factor (EGF) were studied in isolated rat pancreatic acini. CCK8 inhibited 125I-EGF binding in a dose-dependent manner. One-half maximal inhibition occurred at 5 × 10-10M, and maximal inhibition at 10-8M CCK8. This inhibitory effect was detectable within 5 minutes of addition of CCK8, and was not associated with enhanced degradation of 125I-EGF in incubation media. Unlabeled EGF exerted only a slightly greater inhibitory effect than CCK8 on 125I-EGF binding at equivalent molar concentrations. In contrast to CCK8, the gastrointestinal hormone vasoactive intestinal polypeptide (VIP) did not significantly alter EGF binding. CCK8 also inhibited EGF binding in mouse pancreatic acini, but did not alter binding in A-431 human carcinoma cells. These findings suggest that physiological levels of CCK may regulate EGF binding in the pancreas and other tissues with receptors for both hormones. They thus point to a previously unrecognized mechanism for hormonal interaction.

AB - The effects of cholecystokinin-octapeptide (CCK8), the biologically active C-terminal moiety of cholecystokinin (CCK), on the binding of epidermal growth factor (EGF) were studied in isolated rat pancreatic acini. CCK8 inhibited 125I-EGF binding in a dose-dependent manner. One-half maximal inhibition occurred at 5 × 10-10M, and maximal inhibition at 10-8M CCK8. This inhibitory effect was detectable within 5 minutes of addition of CCK8, and was not associated with enhanced degradation of 125I-EGF in incubation media. Unlabeled EGF exerted only a slightly greater inhibitory effect than CCK8 on 125I-EGF binding at equivalent molar concentrations. In contrast to CCK8, the gastrointestinal hormone vasoactive intestinal polypeptide (VIP) did not significantly alter EGF binding. CCK8 also inhibited EGF binding in mouse pancreatic acini, but did not alter binding in A-431 human carcinoma cells. These findings suggest that physiological levels of CCK may regulate EGF binding in the pancreas and other tissues with receptors for both hormones. They thus point to a previously unrecognized mechanism for hormonal interaction.

UR - http://www.scopus.com/inward/record.url?scp=0020532309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020532309&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(83)90131-5

DO - 10.1016/0024-3205(83)90131-5

M3 - Article

C2 - 6310297

AN - SCOPUS:0020532309

VL - 33

SP - 561

EP - 568

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 6

ER -